Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 76

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 76
---
 process, we were initially entitled to, from time to time, sell up to $100 million in the aggregate
of Class A Ordinary Shares, preferred shares, warrants, units, and debt securities. Following the sales made pursuant to the Prospectus
Supplements, we may sell up to approximately $125,000,000 worth of Class A Ordinary Shares in this offering.

The 2020 F-3 expires on January
15, 2023 and therefore, we are filing this registration statement as a new shelf registration statement, with unsold securities and fees
paid under the “expiring” registration statement rolled over herein.

This prospectus also relates
to the resale, by the selling shareholders identified in this prospectus, of up to 540,540 Class A Ordinary Shares underlying outstanding
warrants (the “Selling Shareholder Warrants”) that remain outstanding from the Warrant Supplement. The selling shareholders
are identified in the table commencing on page 27. We will not receive any proceeds from the exercise of the Selling Shareholder Warrants.
See “Use of Proceeds.”

The selling shareholders
may sell all or a portion of the Class A Ordinary Shares, in negotiated transactions or otherwise, and at prices and on terms that
will be determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act
as agent or as or by a combination of such methods of sale. See “Selling Shareholders Plan of Distribution”.

Our Class A Ordinary Shares
are listed on the Nasdaq Global Market under the symbol “APM.” On December 14, 2022, the last reported sale price of our Class
A Ordinary Shares on the Nasdaq Global Market was $0.52 per share. The applicable prospectus supplement will contain information, where
applicable, as to other listings, if any, on the Nasdaq Global Market or other securities exchange of the securities covered by the prospectus
supplement.

Investing in our securities involves a high degree of risk. See “Risk Factors” on page 4 of this prospectus and in the documents incorporated by reference in this prospectus, as updated in the applicable prospectus supplement, any related free writing prospectus and other future filings we make with the Securities and Exchange Commission that are incorporated by reference into this prospectus, for a discussion of the factors you should consider carefully before deciding to purchase our securities.

We may sell these securities
directly to investors, through agents designated from time to time or